2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
65
Stomach Neoplasms
14
Colonic Neoplasms
10
Rectal Neoplasms
5
Triple Negative Breast Neoplasms
3
Sarcoma
3
Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasm Metastasis
2
NSCLC
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Advanced Solid Tumors
2
Advanced Colorectal Carcinoma
2
Unresectable Metastatic Colorectal Cancer
1
To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
1
TAS 102
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Platinum Resistant Ovarian Cancer
1
Patients With Advanced Metastatic Colorectal Cancer
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm, Residual
1
Metastatic Gastroesophageal Junction Adenocarcinoma
1
Metastatic Colorectal Adenocarcinoma
1
Interventions
toripalimab
1
donafenib
1
Oxaliplatin
1
HMPL-013
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Adenocarcinoma
×
HMPL-013
×
Clear all
NCT04156958
2019-11-08
FSTAMBTA
Sichuan University
Phase 2
Unknown
33 enrolled